Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Amgen R&D Entrusted To Ex-Merck Exec; Today's Launches Given To Morrow

  • News

Executive Summary

Amgen is turning to former Merck Exec VP-Worldwide Basic Research & Preclinical Development Roger Perlmutter, MD/PhD, to reinvigorate its R&D program.

You may also be interested in...



GSK Management Triangle: Viehbacher To Head U.S. Rx, Reporting To Stout

GlaxoSmithKline is keeping its Research Triangle Park, N.C. operational center under new U.S. Pharmaceuticals President Christopher Viehbacher

GSK Management Triangle: Viehbacher To Head U.S. Rx, Reporting To Stout

GlaxoSmithKline is keeping its Research Triangle Park, N.C. operational center under new U.S. Pharmaceuticals President Christopher Viehbacher

Biotechnology's "C"-Saw Year: Cialis Boosts Icos, Coviracil Costs Triangle

Icos' upcoming NDA filing for the erectile dysfunction agent Cialis looks like the kind of new product milestone that is playing well with biotech investors heading into 2001.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS037165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By